Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 1/20 | 0.67 |
| ▸ | CDK2 | P24941 | 1/20 | 0.67 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.63 |
| ▸ | MKNK1 | Q9BUB5 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.50 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4040366 | 0.85 | MKNK1 (0.74) | FGFR1MKNK1MAPTMAPK1HTT | |
| SCHEMBL14459745 | 0.84 | CCNA2 (0.49) | CCNA2CDK2CCNA1FGFR1MKNK1 | |
| SCHEMBL1385649 | 0.81 | CCNA2 (0.71) | CCNA2CDK2CCNA1FGFR1MKNK1 | |
| SCHEMBL20259287 | 0.78 | MKNK1 (0.74) | MKNK1 | |
| SCHEMBL17308882 | 0.77 | CCNA2 (0.66) | CCNA2CDK2CCNA1FGFR1MKNK1 | |
| SCHEMBL5629718 | 0.77 | MAPT (0.72) | CCNA2CDK2CCNA1FGFR1MKNK1 | |
| Hydrochloric Acid SCHEMBL5773546 | 0.76 | MAPT (0.71) | CCNA2CDK2CCNA1FGFR1MKNK1 | |
| SCHEMBL17850660 | 0.76 | CCNA2 (0.64) | CCNA2CDK2CCNA1FGFR1MKNK1 | |
| SCHEMBL16756040 | 0.76 | CCNA2 (0.64) | CCNA2CDK2CCNA1FGFR1MKNK1 | |
| SCHEMBL16770180 | 0.76 | CCNA2 (0.64) | CCNA2CDK2CCNA1FGFR1MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4712702-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | claimed |
| US-20060293322-A1 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-28 | — | — | US | claimed |
| EP-1651652-B1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2006-12-27 | — | — | EP | claimed |
| EP-1651652-A1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005010008-A1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| US-7238701-B2 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060293322-A1 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-12-28 | — | — | US | disclosed |
| EP-1651652-B1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2006-12-27 | — | — | EP | disclosed |
| EP-1651652-A1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005010008-A1 | SUBSTITUTED TETRAHYDROBENZOTHIENOPYRIMIDINAMINE COMPOUNDS USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293322-A1 | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders | MKI67, PCNA, MYC | CCNA2 9/4885CDK2 90/4885CCNA1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.